WO2013124863A1 - Process for purification of mbp or mbp tagged proteins - Google Patents

Process for purification of mbp or mbp tagged proteins Download PDF

Info

Publication number
WO2013124863A1
WO2013124863A1 PCT/IN2013/000092 IN2013000092W WO2013124863A1 WO 2013124863 A1 WO2013124863 A1 WO 2013124863A1 IN 2013000092 W IN2013000092 W IN 2013000092W WO 2013124863 A1 WO2013124863 A1 WO 2013124863A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
alginate
mbp
target protein
matrix
Prior art date
Application number
PCT/IN2013/000092
Other languages
English (en)
French (fr)
Inventor
Munishwwar Nath GUPTA
Saurabh GAUTAM
Priyanka DUBEY
Original Assignee
Indian Institute Of Technology Delhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Institute Of Technology Delhi filed Critical Indian Institute Of Technology Delhi
Publication of WO2013124863A1 publication Critical patent/WO2013124863A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag

Definitions

  • This invention relates generally to protein purification.
  • the invention relates to a process for purifying a MBP or MBP tagged protein using alginate matrix and kits for use in the field of protein purification.
  • Protein purification protocol involves a primary stage wherein unit operations like precipitation, membrane based separation separates proteins from other kinds of material, concentrates this feed from the fermenter/crude extract, and also leads to a limited purification of the desired protein. For many industrial applications, this may be an adequate level of purification.
  • Affinity based separation methods generally offer much higher selectivity as compared to separation methods based upon other principles.
  • a ligand having high affinity for the target protein is linked to an insoluble (affinity chromatography) or soluble matrix (affinity precipitation, aqueous two-phase affinity extractions and MLFTPP).
  • a matrix is available which itself has inherent affinity for the target proteins [Gupta M.N., Guoqiang D., aul R., Mattiasson B. Purification of xylanase from Trichoderma viride by precipitation with an anionic polymer Eudragit S 100. Biotechnol. Tech. 8 (1994) 1 17].
  • Recombinant methods offer the possibility of producing the desired proteins with an 'affinity tag' (also called fusion tag) to produce the fusion protein.
  • This enables the purification of the protein directly (skipping many steps) using an affinity based separation.
  • 'affinity tag' also called fusion tag
  • the examples of popular fusion tags are polyhistidine, cellulose binding domain (CBD), Intein tag and MBP [Sachdev D., Chirgwin J.M. Fusions to maltose- binding protein: control of folding and solubility in protein purification, Methods Enzymol. 326 (2000) 312].
  • the core of this technology is designing or selecting a suitable affinity media which would capture the fusion protein via its interaction with 'fusion tag'.
  • MBP as a fusion tag is recommended as it is claimed that a recombinant protein produced with this tag is less likely to form "inclusion bodies".
  • inclusion bodies are inactive solid particles often formed during overexpression of a recombinant protein in bacterial systems. This is believed to be due to aggregation of misfolded proteins. In such cases, the inclusion bodies have to be solubilized (by unfolding) and refolded to recover active soluble protein [Middelberg A.P.J. Preparative protein refolding. Trends Biotechnol. 20 (2002) 437].
  • amylose In the case of MBP-tagged proteins, amylose [Riggs P.D., Hsieh P., Walker I., Colussi P.
  • MBP maltose binding protein
  • the maltose-binding protein (MBP) is a 40.70 kDa, 370 amino acid, periplasmic protein of E. coli 12, involved in binding and transport of maltose and is encoded by the malE gene.
  • the MBP can be fused at the N- or C-terminus of the protein if overexpression in bacteria is desired [Sachdev D., Chirgwin J.M. Fusions to maltose-binding protein: control of folding and solubility in protein purification. Methods Enzymol. 326 (2000) 312].
  • affinity matrices For purifying MBP-tagged proteins, two affinity matrices are commercially available viz. amylose resin by New England Biolabs and Dextrin sepharose by GE Healthcare. Unlike above quoted commercially available matrices, alginate can be viewed as a smart (Ca 2+ responsive), a stimuli sensitive or reversible soluble insoluble polymer. Hence a non chromatographic approach called affinity precipitation [Mondal ., Gupta M.N., Roy I. Affinity-based strategies for protein purification. Anal. Chem. 78 (2006a) 3499] can be used for purifying proteins. Affinity precipitation is a scalable inexpensive batch process with many advantages [Mondal et al. (2006a)] over chromatographic methods.
  • US patent 5643758 describes a method for producing and/or purifying any hybrid polypeptide molecule employing recombinant DNA techniques.
  • the method as described involves expression of hybrid polypeptide comprising a binding protein that can be purified by contacting the hybrid polypeptide with a ligand or substrate to which the binding protein has specific affinity for example affinity chromatography.
  • Alginate is known to bind some carbohydrate binding enzymes [Teotia S., Khare S.K., Gupta M.N. An efficient purification process for sweet potato beta-amylase by affinity precipitation with alginate. Enzyme Microb. Tech. 28 (2001 ) 792] and can be used in affinity based separations in packed bed [Jain S, Gupta MN. Purification of goat immunoglobulin G by immobilized metal-ion affinity using cross-linked alginate beads. Biotechnol. Appl. Biochem. 39 (2004) 319], fluidized bed [Roy I., Jain S., Teotia S., Gupta M.N.
  • the present invention provides a solution to this problem by providing a process of purification of proteins whereby all contaminating proteins or impurities are at least partially, preferably completely, removed in a single purification step.
  • the invention also provides for a simultaneous refolding strategy in case the starting preparation is in inactive form including inclusion bodies.
  • Another aspect of the present invention provides a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein-alginate complex, and purifying the target protein from the protein-alginate complex.
  • Yet another aspect of the present invention provides a protein purification process, comprising permitting a sample comprising a target protein to bind to a matrix comprising 0.1 % to 2.0% (w/v) alginate, wherein the target protein is MBP or MBP tagged protein; and purifying the target protein from the matrix in a selected buffer to obtain the purified target protein.
  • Still another aspect of the present invention provides a process for purifying a target protein, wherein the process comprises providing a DNA expression vector capable of expressing a target protein in a host cell, wherein the target protein is tagged with MBP; transforming a host cell with the DNA expression vector and expressing the target protein; contacting the target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, separating the protein-alginate complex, and purifying the target protein from the protein-alginate complex, wherein purified target protein is capable of refolding into their native conformation.
  • Still yet another aspect of the present invention provides a device for selective binding and separation of a MBP or MBP tagged target protein from a sample, wherein the device comprising housing, an inlet, an outlet and at least one separation matrix comprising alginate or alginate beads.
  • Further aspect of the present invention is to provide a protein purification kit comprising the device comprising housing, an inlet, an outlet, and at least one separation matrix comprising alginate or alginate beads, a precipitation and washing buffer comprising CaCl 2 , and an elution buffer comprising maltose or a suitable eluent.
  • Figure 1 shows SDS-PAGE analysis of the MBP and MBP fusion proteins purified by alginate.
  • protein refers to a polymer of amino acid residues.
  • polypeptide refers to a polymer of amino acid residues.
  • the terms also apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.
  • Peptides are distinguished by the number of amino acid residues making up the primary structure of the molecule.
  • peptides are those molecules comprising up to 50 amino acid residues and proteins comprise more than 50 amino acid residues.
  • fusion protein and “target protein” used herein can be used interchangeably.
  • MBP tagged Protein and “MBP tagged fusion Protein” used herein can be used interchangeably.
  • Purifying a target protein from a sample comprising the target protein and one or more contaminating proteins or impurities refers to increasing the degree of purity of the target protein by removing partially or completely at least one or more of the contaminating proteins or impurities.
  • Recombinant protein or "fusion protein” as used herein refers to a protein which has been produced in a host cell which has been transformed or transfected with nucleic acid encoding the protein, or produces the protein as a result of homologous recombination.
  • sample refers to any composition, preferably an aqueous solution that comprises a target protein group of interest and contaminating proteins and is in a physical state which allows any target protein group of interest and any contaminating protein present in the sample to be contacted with a library of binding moieties.
  • Samples may be of any source that comprises MBP or MBP tagged target protein of interest.
  • Solid support refers to any insoluble material including particles (e.g., beads), fibers, monoliths, membranes, filters, plastic strips, and the like.
  • a protein can exist in a sample in several forms that can be co-purified.
  • target protein refers to a single protein or group of related proteins to be purified. These related forms can result from either, or both, of pre-and post- translational modification.
  • Pre-translational modified forms include allelic variants, , slice variants, and RNA editing forms.
  • Post-translationally modified forms include forms resulting from proteolytic cleavage (e.g., fragments of a parent protein), glycosylation, phosphorylation, lipidation, oxidation, methylation, cystinylation, sulphonation and acetylation.
  • a protein of interest a protein of interest
  • albumin and modified forms of albumin found in serum are a target protein.
  • a protein may be expressed as a multimeric protein, such as a dimeric protein. Examples of this are immunoglobulins and insulin.
  • a protein of interest embraces this as well.
  • the present invention provides a novel matrix for MBP or MBP tagged target protein, wherein the novel matrix is comprised of alginate. More particularly, the present invention provides a process for purifying virtually any MBP tagged recombinant protein using the alginate matrix that results in recovery of about 96% to 99.9% of the target protein.
  • the protein purification process as disclosed in the present invention does not employ costly reagents with their attendant disposal problems, does not require multiple steps, and results in high yield of a pure, biologically active protein product.
  • the present invention provides a process for obtaining highly purified virtually any protein molecule produced by recombinant technology in a single step or if necessary another chromatographic step followed by it, wherein the protein is tagged with MBP.
  • the present invention provides a process for purifying a target protein in the form of fusion protein comprising MBP as a binding protein produced by recombinant DNA technology.
  • the fusion protein can be isolated and purify directly from the crude extract or culture medium by contacting the extract or the culture medium comprising the fusion protein to the alginate matrix as disclosed in the present invention.
  • the purified target protein comprising the binding protein can be further processed to separate the binding protein. It can be performed by various methods known in the art such as using a linker DAN sequence for linking a DNA encoding binding protein and a DNA encoding protein of interest to obtain a fusion protein.
  • the MBP or MBP tagged target protein comprising the a protein of interest is produced by constructing a cloning vector containing fused genes comprising a gene encoding a protein molecule of interest and a gene coding for a MBP or a portion or a variant thereof which has a specific affinity for alginate and expressing the fusion in suitable host cell such as E. coli, yeast, animal cell, insect cell or plant cell.
  • the protein purification processes as described herein by which DNA coding for a fusion protein comprising a protein of interest and MBP or a portion or a variant thereof is preferably cloned, expressed and purified using the alginate matrix as disclosed in the present invention.
  • the process comprises constructing a recombinant fusion DNA expression cassette, wherein the DNA expression cassette comprises the polynucleotide encoding MBP or fragment thereof or a variant thereof and a polynucleotide encoding the protein of interest operably linked to a promoter, producing a recombinant vector comprising the recombinant fusion DNA expression cassette, transforming the recombinant vector into an appropriate host such as E.
  • coli selecting the transformants with antibiotic selection or other phenotypic selection, expressing the fusion protein in an appropriate host cell such as E. coli, yeast, animal cell, insect cell or plant cell and purifying the fusion protein comprising the MBP or MBP tagged by contacting crude protein sample or the culture medium potentially comprising the target protein with a matrix comprising 0.1% to 2.0% (w/v) preferably 0.5% (w/v) alginate to obtain a protein-alginate complex, separating the protein-alginate complex by adding CaCl 2 solution to a final concentration of 0.06M, and purifying the target protein from the protein-alginate complex by adding CaCl 2 solution to a final concentration of 0.06M.
  • an appropriate host cell such as E. coli, yeast, animal cell, insect cell or plant cell and purifying the fusion protein comprising the MBP or MBP tagged by contacting crude protein sample or the culture medium potentially comprising the target protein with a matrix comprising 0.1% to 2.0% (w/v) preferably 0.5% (w/
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein- alginate complex, and purifying the target protein from the protein-alginate complex.
  • the protein purification process as disclosed in the present invention is applicable to industrial-scale purification as a new purification procedure.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.5% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein-alginate complex, and purifying the target protein from the protein-alginate complex.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.5% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein-alginate complex, and purifying the target protein from the protein-alginate complex, wherein the matrix further comprises one or more composite material selected from a group consisting of chitosan, starch, cellulose, dextran, carrageenan, proteins such as gelatin, oxides, Si0 2 , heparin, and Hyaluronic acid.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein-alginate complex by adding CaCl 2 solution to a final concentration of 0.06M, and purifying the target protein from the protein-alginate complex.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein-alginate complex, washing of the protein-alginate complex, and purifying the target protein from the protein-alginate complex.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein- alginate complex, washing of the protein-alginate complex of step (b) by adding CaCl 2 solution to a final concentration of 0.06M, and purifying the target protein from the protein-alginate complex.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein- alginate complex, and purifying the target protein from the protein-alginate complex by adding 1M Maltose solution at 4°C to 25°C preferably at 4°C for 1-24 hours preferably for 18 hours.
  • a protein purification process comprising contacting a sample comprising a target protein with a matrix comprising 0.5% (w/v) alginate at 25°C ⁇ 2 to obtain a protein-alginate complex, wherein the target protein is MBP or MBP tagged protein; separating the protein- alginate complex by adding CaCl 2 solution to a final concentration of 0.06M, washing the protein-alginate complex with a buffer comprising 0.06M CaCl 2 and purifying the target protein from the protein-alginate complex by adding 1M Maltose solution at 4°C to 25°C preferably at 4°C for 1-24 hours preferably for 18 hours.
  • Yet another embodiment of the present invention provides a protein purification process comprising permitting a sample comprising a target protein to bind to a matrix comprising 0.1% to 2.0% (w/v) alginate, wherein the target protein is MBP or MBP tagged protein; and purifying the target protein from the matrix in a selected buffer to obtain the purified target protein.
  • Still another embodiment of the present invention provides a process for producing and purifying a target protein, wherein the process comprises producing the target protein by transforming a host cell with a recombinant vector comprising a DNA expression cassette comprising the polynucleotide encoding the target protein, wherein the target protein is tagged with MBP; contacting the target protein with a matrix comprising 0.1% to 2.0% (w/v) alginate to obtain a protein-alginate complex, separating the protein-alginate complex, and purifying the target protein from the protein-alginate complex.
  • Still another embodiment of the present invention provides a process for producing and purifying a recombinant MBP protein, wherein the process comprises producing the recombinant MBP protein in a host cell by transforming the host cell with a recombinant vector comprising a DNA expression cassette comprising a polynucleotide encoding the recombinant MBP (maltose-binding protein) protein, contacting the recombinant MBP protein with a matrix comprising 0.5% (w/v) alginate to obtain a MBP protein-alginate complex, separating the MBP protein-alginate complex, and purifying the recombinant MBP protein from the MBP protein-alginate complex.
  • Still another embodiment of the present invention provides a process for producing and purifying a recombinant MBP tagged CD4bs (a fragment of HIV protein gpl20) fusion protein, wherein the process comprises producing the recombinant MBP tagged CD4bs fusion protein in a host cell by transforming the host cell with a recombinant vector comprising a DNA expression cassette comprising a polynucleotide encoding the recombinant MBP tagged CD4bs fusion protein, contacting the recombinant MBP tagged CD4bs fusion protein with a matrix comprising 0.5% (w/v) alginate to obtain a MBP tagged CD4bs-alginate complex, separating the MBP protein-alginate complex, and purifying the MBP protein tagged CD4bs fusion from the MBP tagged CD4bs- alginate complex.
  • Still another embodiment of the present invention provides a process for producing and purifying a recombinant MBP tagged H3HA9 (one of the influenza hemagglutinin) fusion protein, wherein the process comprises producing the recombinant MBP tagged H3HA9 fusion protein by transforming a host cell with a recombinant vector comprising a DNA expression cassette comprising a polynucleotide encoding the MBP tagged H3HA9 fusion protein, contacting the MBP tagged H3HA9 fusion protein with a matrix comprising 0.5% (w/v) alginate to obtain a MBP tagged H3HA9-alginate complex, separating the MBP protein-alginate complex, and purifying the MBP tagged H3HA9 fusion protein from the MBP tagged H3HA9-alginate complex.
  • One embodiment of the present invention relates to a host cell for production of recombinant MBP or MBP tagged fusion protein, wherein the host cell is a bacterial cell such as E. coli or yeast or fungal cell or mammalian cell or plant cell or a similar organism capable of producing the protein.
  • the host cell is a bacterial cell such as E. coli or yeast or fungal cell or mammalian cell or plant cell or a similar organism capable of producing the protein.
  • the alginate matrix based protein purification method as disclosed in the present invention results in higher yield of pure MBP or MBP tagged target protein.
  • the alginate matrix based protein purification method of the present invention purifies at least 96% of the target protein is purified, more preferably at least 97%, most preferably at least 98%.
  • the alginate matrix based protein purification method for purification of MBP tagged target protein of the present invention can purify up to 99% to 99.9% of the target protein.
  • the process of protein purification as disclosed in the present invention is able to purify more than 98% preferably mere that 99% of target protein which is in the form of a soluble protein or in the form of inclusion body.
  • inclusion bodies surprisingly it was found out that the protein in the form solubilized inclusion bodies purified using the alginate matrix as disclosed in the present invention is capable of refolding into their native conformation. If the MBP tagged fusion protein is expressed as inactive and insoluble inclusion bodies, then refolding and simultaneous purification of the protein can be carried out by alginate matrix as disclosed in the present invention from the inclusion bodies. In case refolding along with purification is desired from the inclusion bodies then before refolding and purification, solubilization of inclusion bodies in 8 M urea or 6 M GdmCl (guanidium chloride) or by any other means is carried out.
  • the process for protein purification as disclosed in the present invention can be carried out in following modes:
  • Batch mode By precipitation of the protein-alginate complex by adding 0.06 M CaC12 and then elution/dissociation of protein-polymer complex by maltose or by any other suitable means (depending upon the target protein).
  • alginate concentration can be generally varied from 0.1% to 5%.
  • Packed bed column mode A chromatographic column is packed with alginate beads and the purification is carried out as affinity chromatography. Here the alginate beads are packed in a column and then the purification is carried out.
  • Expanded (stable fluidized) bed column mode Purification is carried out in expanded (stable fluidized) bed column chromatography mode by using alginate beads. Here the alginate beads are loaded on a fluidized bed column.
  • Alginate can be converted into magnetic beads by coating of particles (such as Fe 3 0 4 particles) of any size (for nanoparticles, micron size particles etc.) with alginate, and then magnetic separation of protein-alginate (alginate is magnetic) complex by the means of a magnet.
  • particles such as Fe 3 0 4 particles
  • Alginate is magnetic
  • Elution or dissociation of the purified MBP tagged fusion protein from the alginate in all the above modes was carried out by using 1 M Maltose, wherein the concentration of Maltose is in the range of 0.05 M to 2 M.
  • the final purity of the purified protein obtained using the alginate matrix as disclosed in the present invention is more than 98% or up to 99.9% as observed by densitometer analysis of SDS-PAGE, which is even higher as compared to any known process of protein purification using Dextrin Sepharose matrix (GE Healthcare) which yields 95% purity by SDS-PAGE.
  • Another embodiment of the present invention provides a device for selective binding and separation of a MBP or MBP tagged target protein from a sample, wherein the device comprising housing, an inlet, an outlet and at least one separation matrix comprising alginate or alginate beads.
  • Another embodiment of the present invention related the device as disclosed in the present invention, wherein the device comprises alginate matrix in the form of alginate beads.
  • Another embodiment of the present invention related the device as disclosed in the present invention, wherein the device comprises alginate matrix in the form of magnetic alginate beads.
  • Another embodiment of the present invention related the device as disclosed in the present invention, wherein the device is packed bed column or fluidized bed column.
  • the alginate can be converted into magnetic beads by coating of particles (such as Fe 3 0 4 particles) of any size (for nanoparticles, micron size particles etc.) with alginate and then magnetic separation of protein-alginate (alginate is magnetic) complex by the means of a magnet.
  • the present invention further provides a matrix comprising alginate (0.1 % to 2%) for purification of MBP or MBP tagged protein, wherein the matrix further comprises composite materials including polysaccharides e.g. chitosan, starch, cellulose, dextran and carrageenan; proteins, e.g. gelatin; oxides e.g. Si0 2 as a core or coat material, heparin, Hyaluronic acid etc.
  • alginate matrix beads as disclosed in the present invention particles can be of various sizes including nanodimensions made up of either alginate alone or in combination with composite materials including polysaccharides e.g. chitosan, starch, cellulose, dextran and carrageenan; proteins, e.g. gelatin; oxides e.g. Si0 2 as a core or coat material, heparin, Hyaluronic acid etc.
  • polysaccharides e.g. chitosan, starch, cellulose, dextran and carrageenan
  • proteins e.g. gelatin
  • oxides e.g. Si0 2 as a core or coat material heparin, Hyaluronic acid etc.
  • Yet another embodiment of the present invention provides a protein purification kit comprising housing, an inlet, an outlet, and at least one separation matrix comprising alginate or alginate beads, a precipitation and washing buffer comprising CaCl 2 , and an elution buffer comprising Maltose or a suitable eluent.
  • the inventors of the present invention unexpectedly found out that about 99 to 99% MBP tagged target protein can be obtained using alginate matrix in purification process and thus the simple alginate which is an inexpensive, non-toxic food grade polysaccharide of marine origin emerged as more useful matrix than existing options of amylase resin and dextrin sepharose.
  • alginate based strategies precipitation, packed bed, fluidized bed etc.
  • alginate based strategies will be able to simultaneously refold the fusion proteins as well.
  • alginate refolded urea denatured amylase Mondal K., Raghava S., Barua B., Varadarajan R., Gupta M.N. Role of stimuli-sensitive polymers in protein refolding: a- Amylase and CcdB (controller of cell division or death B) as model proteins, Langmuir 23 (2007) 70].
  • One embodiment provides a process of purification of MBP or MBP tagged recombinant protein using the alginate matrix and suitable buffers, wherein the alginate matrix is in form of beads.
  • the alginate beads matrix of the present invention can be in form of magnetic beads.
  • Another embodiment of the present invention provides a process of purification of MBP or MBP tagged target, recombinant protein using alginate solutions (0.1 % to 2%) and polymer such as PEG as one phase and polymer/salt solution of as another phase for carrying out separation of the target recombinant protein using Aqueous two-phase systems.
  • Another embodiment of the present invention provides a process of purification of MBP or MBP tagged target recombinant protein using alginate solutions (0.1% to 2%) and polymer such as PEG as one phase and polymer/salt solution of as another phase for carrying out separation of the target recombinant protein using Aqueous two-phase systems.
  • An aqueous two-phase system forms when two types of water soluble polymers or a water soluble polymer and a low molecular weight substance (inorganic salt in general) dissolve in aqueous solution above their critical concentrations.
  • the top phase is rich in one polymer, and the bottom phase is rich in the other polymer or the salt. Both the two phases contain water at high proportion (about 80-99% by weight), and possess extremely low interfacial tensions.
  • ATPSs provide different physical and chemical environments which allow for the partitioning of biomolecules such as proteins, plasmid DNA, toxin and so on.
  • compositions including polymer/polymer, polymer/salt, surfactants, are important examples for ATPS in protein separation.
  • Another embodiment of the present invention provides a process of purification of MBP or MBP tagged target recombinant protein using alginate solutions (0.1% to 2%) using multi-phase systems.
  • Multiphasic systems consist of more than two phases.
  • TPP systems or MLFTPP systems are TPP systems or MLFTPP systems.
  • alginate-target protein complex are known to separate as interfacial layer when appropriate amounts of a salt such as ammonium sulphate and an organic solvent (such as t-butanol) is mixed to a crude extract of protein [Sharma A., Roy I., Gupta M.N. Affinity precipitation and macroaffmity ligand facilitated three-phase partitioning for refolding and simultaneous purification of urea-denatured pectinase. Biotechnol. Progr. 20 (2004) 1255]. As is shown in the above reference, alginate can again simultaneously refold even in such systems.
  • Protanal LF 10/60 (free alginate from brown seaweed) having a high content of guluronic acid (65-75%) was a product of Protan A/S (Drammen, Norway).
  • the average molecular weight of Protanal LF 10/60 is 3,20,000 g/mol [Amsden B., Turner N. Diffusion characteristics of calcium alginate gels. Biotechnol. Bioeng. 65 (1999) 605].
  • PMSF phenylmethanesulfonyl fluoride
  • ampicillin were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). All the other chemicals were of analytical reagent quality.
  • E. coli DH5a was used for wild type (WT) MBP and BL21 (DE3) for MBP fusion proteins with CD4bs and H3HA9.
  • the plasmid pMALp2 expressing WT-MBP was transformed into E. coli DH5a.
  • a single colony was picked and inoculated into 5 mL LB medium containing 100 ⁇ g/mL _1 ampicillin.
  • the tubes were shaken overnight at 37°C at 200 rpm.
  • One percent of primary inoculum was transferred into 1 L fresh LB broth (amp+) and grown at 37°C with vigorous shaking until OD 600 reached 0.8.
  • Induction was carried out by adding isopropyl-P-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and the culture was further grown under similar conditions for 12 h at 37°C at 200 rpm. This procedure was repeated for the transformation of the plasmid pET-22b-HMGWA containing MBP-CD4bs fusion protein into E. coli BL21 (DE3) and expressed.
  • the plasmid pET-22b(+) expressing MBP-H3HA9 fusion protein was transformed into E. coli BL21 (DE3) and the culture was grown culture at 37°C with vigorous shaking until OD 600 reached 0.6-0.8 and the culture was further grown at 25°C for 12 h at 200 rpm after induction with 1 mM IPTG.
  • the cells were harvested by centrifugation at 8000 xg for 10 min at 4°C. Crude MBP was isolated from E. coli cells employing the osmotic shock procedure [Ganesh C, Shah A.N., Swaminathan CP., Surolia A., Varadarajan R. Thermodynamic Characterization of the reversible, two-state unfolding of maltose-binding protein, a large two-domain protein. Biochemistry 36 (1997) 5020]. The cells were washed twice with one-tenth of the culture volume of OSF 1 (10 mM Tris, 30 mM NaCl, and 100 ⁇ PMSF at pH 7.2).
  • OSF 1 10 mM Tris, 30 mM NaCl, and 100 ⁇ PMSF at pH 7.2
  • the washed pellet was then resuspended in one twentieth of the culture volume of OSF II (30 mM Tris, 0.1 mM EDTA, 100 ⁇ PMSF, and 20% w/v sucrose at pH 7.2), stirred at room temperature for 20 min, and then pelleted at 8500g for 20 min.
  • the cell pellet was osmotically shocked by resuspending the cells in one- tenth of the culture volume of ice-cold OSF III (100 ⁇ MgC12 and 100 ⁇ PMSF) and stirred at 4°C for 20 min.
  • the suspension was centrifuged at 1 1 OOOg for 20 min, and the supernatant so obtained is the OSF.
  • Tris-HCl, MgC12, and PMSF were added to final concentrations of 10 mM, 2 mM, and 100 ⁇ , respectively, and the pH was adjusted to 7.5 at 4°C.
  • MBP-H3HA9 and MBP-CD4bs fusion proteins were isolated from E. coli cells by sonication in 50 mM Tris-HCl buffer, pH 7.5, containing 100 ⁇ PMSF, 10 times with 30 s pulses on ice, and centrifugation at 9000 xg for 30 min at 4°C. The supernatant thus obtained was used as crude extract for MBP-CD4bs and MBp-H3HA9 fusion proteins.
  • Alginate beads were prepared as described earlier [Roy et al. (2004)]. Beads were formed by dropping 50 mL of 2% (w/v) alginate solution through a syringe into 100 mL of 0.1 M CaCl 2 solution. The beads obtained were kept for 2 h in 0.1 M CaCl 2 solution and stored in a 0.006M CaCl 2 solution at 4 °C.
  • the alginate microbeads were also prepared as described previously [Roy et al. (2004)]. 100 mL of alginate solution (2%, w/v) was taken in a handheld glass sprayer (normally used for spraying chromatograms) (16), one end of which was connected to the air cylinder. Alginate solution was sprayed into 500 mL of 1 M CaC12 solution, at a constant pressure of 2 kg cm-2. The microbeads formed were filtered after 2 h on a Bu " chner funnel under vacuum and dried overnight in the oven at 50 °C.
  • Cross-linked alginate beads were prepared as described earlier [Sharma S., Roy I., Gupta M.N. Separation of phospholiase D from peanut on a fluidized bed of crosslinked alginate beads. Biochem. Eng. J. 8 (2001) 235].
  • Alginate was added to an alcoholic solution of epichlorohydrin (3 ml of epichlorohydrin in 15 ml of 95% ethanol). A total of 5 ml of 5N NaOH was added to this mixture and the suspension was gently rotated at 50 rpm for 8 h on a rotatory evaporator bath kept at 40 °C. Thereafter, the mixture was neutralized to pH 7.0 with 1M acetic acid.
  • the cross-linked alginate beads thus formed were washed with 30 ml of a 3: 1 mixture (v/v) of absolute ethanol and water, followed by 20 ml of 95% ethanol.
  • the matrix was left to dry to constantweight at room temperature.
  • the dried material was resuspended in 50 ml of distilled water, stirred and left to dry at constant temperature.
  • the suspension was decanted and the material remaining at the bottom of the beaker was collected on a coarse sintered glass filter, washed with 20 ml of 95% ethanol, dried again at room temperature to constant weight.
  • the matrix was finally resuspended and equilibrated in a suitable buffer for 30 min before use.
  • Alginate solution (20 ml, 2% w/v) was taken into 80 ml of Fe30 4 nanoparticles (0.5 g/100 ml) suspensions, the mixture was stirred at 50 °C for 45 min, and then the coated nanoparticles were separated by the means of a magnet and washed with double distilled water.
  • Alginate solution (2%, w/v) was prepared in distilled water by dissolving 1 g of alginate in 50 mL of water. The solution was stored at 4°C and diluted with appropriate buffer for further use [Mondal K., Bohidar H.B., Roy R.P., Gupta M.N. Alginate-chaperoned facile refolding of Chromobacterium viscosum lipase. Biochim. Biophys. Acta. 439 (2006b) 1017]. Purification by Affinity Precipitation
  • the precipitate was then washed twice with 2 mL of 0.05 M Tris-HCl buffer, pH 7.5, containing 0.06 M CaCl 2 .
  • the bound protein was eluted off of the alginate by suspending the alginate-protein complex in 2 mL of chilled 1 M Maltose (prepared in 50 mM Tris-HCl buffer, pH 7.5) and incubating this suspension at 4°C for 18 h.
  • Phase systems were prepared in graduated centrifuge tubes by mixing 22% (w/v) PEG 6000, 10% (w/v) dipotassium hydrogen orthophosphate, 10% (w/v) sodium chloride. The two distinct phases were formed within 5 min. To this aqueous two-phase system 0.5% (w/v) alginate was incorporated. Thereafter, crude preparations of WT-MBP, MBP-CD4bs and MBP-H3HA9 fusion proteins (1.0 ml) were added to the corresponding systems. Alginate distribution was restricted to the PEG phase with less than 5% (of the initially added amount) going to the bottom phase. Alginate concentration in the two phases was estimated by the phenol-sulphuric acid method [Hirs C.H.W.
  • WT-MBP, MBP-CD4bs and MBP-H3HA9 fusion proteins were added to 1ml alginate (0.5%, w/v).
  • the final volume was made up to 2 ml with 0.05M Tris-HCl buffer, pH 7.0.
  • the protein containing solution was made up " to 30% (w/v) with respect to ammonium sulfate and 4ml t-butanol was added.
  • gentle vortexing was followed by incubating the systems at 37°C for 1 h. Formation of three phases (upper organic phase, interfacial precipitate, and lower aqueous phase) was observed.
  • the upper t-butanol layer was removed carefully with a Pasteur pipette.
  • the lower aqueous layer was removed by piercing the interfacial precipitate layer using another Pasteur pipette.
  • the difference between the total protein in the crude extract and the protein in the aqueous phase represented the amount of protein bound to the alginate in the interfacial layer.
  • the interfacial precipitate consisting of alginate bound protein was dissolved in 3 ml of 1M maltose and incubated at 4°C for 4 h. Protein was then recovered by precipitating the alginate with 0.21 ml of 1M CaCl 2 (the final concentration of CaCl 2 in the solution was 0.07M). Protein activity and the protein concentration in the supernatant were determined after extensive dialysis to remove maltose.
  • Protein concentration was estimated by the dye binding method using bovine serum albumin as the standard protein [Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248].

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
PCT/IN2013/000092 2012-02-21 2013-02-13 Process for purification of mbp or mbp tagged proteins WO2013124863A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN483/DEL/2012 2012-02-21
IN483DE2012 IN2012DE00483A (enrdf_load_stackoverflow) 2012-02-21 2013-02-13

Publications (1)

Publication Number Publication Date
WO2013124863A1 true WO2013124863A1 (en) 2013-08-29

Family

ID=49005104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000092 WO2013124863A1 (en) 2012-02-21 2013-02-13 Process for purification of mbp or mbp tagged proteins

Country Status (2)

Country Link
IN (1) IN2012DE00483A (enrdf_load_stackoverflow)
WO (1) WO2013124863A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019360A1 (de) * 2016-07-25 2018-02-01 Aj Innuscreen Gmbh Verfahren zur anreicherung von biomolekülen und zur entfernung der biomoleküle aus einer biologischen probe
EP4345162A1 (de) * 2022-09-27 2024-04-03 LGC Genomics GmbH Partikel mit oligomeren und/oder polymeren uronsäuren zur anreicherung von biologischem material

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099777A2 (en) * 2003-05-02 2004-11-18 Becton, Dickinson And Company Multicoated or multilayer entrapment matrix for protein biosensor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099777A2 (en) * 2003-05-02 2004-11-18 Becton, Dickinson And Company Multicoated or multilayer entrapment matrix for protein biosensor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MONDAL, K. ET AL.: "Macroaffinity Ligand-Facilitated Three-Phase Partitioning for Purification of Glucoamylase and Pullulanase Using Alginate", PROTEIN EXPRESSION AND PURIFICATION, vol. 28, 2003, pages 190 - 195, XP055082017 *
MUMMA, K. ET AL.: "Crystal Structure ot AlgQ2, a Macromolecule (Alginate)-Binding Protein of Sphingomonas sp. A1 at 2.0A Resolution", JOURNAL OF MOLECULAR BIOLOGY, vol. 316, 2002, pages 1051 - 1059, XP004472479 *
ROY, I. ET AL.: "Purification of a Bacterial Pullulanase on a Fluidized Bed of Calcium Alginate Beads", JOURNAL OF CHROMATOGRAPHY A, vol. 950, 2002, pages 131 - 137, XP004339527 *
SARDAR, M. ET AL.: "Alginate Beads as an Affinity Material for Alpha Amylases", BIOSEPARATION, vol. 7, no. 3, 1998, pages 159 - 165, XP019232347 *
TEOTIA, S. ET AL.: "Magnetite-Alginate Beads for Purification of Some Starch Degrading Enzymes", MOLECULAR BIOTECHNOLOGY, vol. 20, no. 3, 2002, pages 231 - 237, XP055082013 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019360A1 (de) * 2016-07-25 2018-02-01 Aj Innuscreen Gmbh Verfahren zur anreicherung von biomolekülen und zur entfernung der biomoleküle aus einer biologischen probe
CN110167952A (zh) * 2016-07-25 2019-08-23 Aj耶拿检疫有限公司 用于富集生物分子并且用于从生物样品中去除这些生物分子的方法
US11352617B2 (en) 2016-07-25 2022-06-07 Ist Innuscreen Gmbh Method for enriching biomolecules and for removing the biomolecules from a biological sample
EP4345162A1 (de) * 2022-09-27 2024-04-03 LGC Genomics GmbH Partikel mit oligomeren und/oder polymeren uronsäuren zur anreicherung von biologischem material

Also Published As

Publication number Publication date
IN2012DE00483A (enrdf_load_stackoverflow) 2015-06-05

Similar Documents

Publication Publication Date Title
US8329877B2 (en) Methods for separating recombinant proteins in aqueous two-phase systems
KR101831300B1 (ko) 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
JP2002543766A (ja) タンパク質を分離する方法
JP2006304633A (ja) イムノグロブリン結合タンパク質
CN104211769B (zh) 一种小分子抗体亲和肽及其应用
JPH06102034B2 (ja) タンパク質の生産方法
US20230203109A1 (en) Fusion polypeptides for target peptide production
CN113025675B (zh) 多肽的制备方法
JP2023502335A (ja) スプリットインテインシステムを使用したタンパク質精製
Gautam et al. Non-chromatographic strategies for protein refolding
Zeng et al. Macroporous chitin affinity membranes for wheat germ agglutinin purification from wheat germ
Gupta et al. Three phase partitioning: applications in separation and purification of biological molecules and natural products
AU2004269198B2 (en) A process for proteolytic cleavage and purification of recombinant proteins produced in plants
WO2013124863A1 (en) Process for purification of mbp or mbp tagged proteins
JP4088584B2 (ja) 融合タンパク質から目的タンパク質を分離する方法。
WO2014177021A1 (zh) 强分泌性信号肽增强小肽模序及其应用
CN109721645A (zh) 一种基因突变的蛋白a及其应用
CN101885753A (zh) 蛋白质纯化的方法及系统
CN113845585A (zh) 使用金属螯合色谱法去除重组人生长激素内毒素的方法
CN108220273A (zh) 一种抗菌肽混合物及其制备方法和应用
Hochuli Purification techniques for biological products
US20240279289A1 (en) Methods of recombinant production of lectins
CN113493780A (zh) 一种利用sumo融合表达系统制备重组肝素酶ii的方法及其所制备的sumo_肝素酶ii融合蛋白
CN118667037B (zh) 一种用于结合内毒素的融合蛋白elp-ebp及其制备方法和去除水溶液中内毒素方法
CN104888205B (zh) 长牡蛎C型凝集素-3(CgCLec-3)重组蛋白的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13752400

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13752400

Country of ref document: EP

Kind code of ref document: A1